EP174: Real World Data vs Real World Evidence, Especially for Pharma, With Julie Locklear From Genesis Research
March 15, 2018
174
33:39

EP174: Real World Data vs Real World Evidence, Especially for Pharma, With Julie Locklear From Genesis Research

Julie is an executive pharmaceutical leader with over 20 years of experience across all phases of development both on the commercial and research sides of the organization. She leverages her Masters in Business Administration and Doctorate of Pharmacy to develop and deliver strategic patient-centric value propositions to optimize patient access and improve outcomes in patients with difficult to treat diseases leading to longer, healthier, and more productive lives. Her years of experience in global and US payer markets provides Julie with intimate knowledge of the current and evolving payer and market access landscape in the United States and around the globe. She has led the development and execution of several outcomes-based contracts with 3 of the largest national payer organizations in the US.


Julie is well published, having authored more than 30 publications in peer-reviewed journals and more than 60 peer-reviewed abstracts presented as posters at major scientific congresses.


00:00 Julie’s earlier episode - EP144 - the “prequel” to this episode.
01:45 Innovative contracting and outcomes based agreements.
02:00 Real World Data vs Real World Evidence.
03:15 The reason behind the Real World Data lag in health care.
03:35 Value-based pricing.
05:00 Who has the best information on a specific product according to who owns patient population Real World Data.
05:45 What Real World Evidence is, and how it differs from Real World Data.
06:15 How Real World Evidence stems from Real World Data.
07:20 Who hires these organizations and how they fit into the value chain.
09:10 Leveraging this data into workflows.
10:30 How pharma companies will utilize Real World Data.
13:35 Are pharma manufacturers being affected by Real World Evidence or Real World Data?
16:00 Is needing Real World Evidence becoming more prominent to US health care?
18:25 The different types of data and how that affects what sorts of conclusions various payers can come to.
21:30 The current gap for physicians at the point of care.
28:25 “Collaboration is a core skill.”
29:15 “You need to first ask around - you don’t know what you don’t know.”
30:25 “One of the most important things early on is just to listen.”
32:30 Genesis Research and their work.

healthcare,pharma,genesis research,real world data vs evidence,value-based pricing,
|
|

Episode Support Provided By

Special Thanks to Our 2026 Sustaining Monthly Donors

Marilyn Bartlett, Kimberly Carleson, Dylan Yahn, Benjamin Light, Matt McQuide, Ann Kempski, Spencer Allen, Scott Tromanhauser, 
Steven Elkins, Matthew Bunte, and Lori Smith.

Recent Episodes

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio
Relentless Health ValueOctober 14, 2026
533
37:1334.07 MB

EP533: Level Funding Is Self-funding: 5 Avoidable Contract Risks, With Frank Pennachio

Hello, all you Relentless Tribe members. Thanks for hanging with me today to talk about a bunch of things. One of them being what exactly are level-funded plans, and what are the upsides, and then what are the risks? Because here's the thing. I was talking to an employer the other day, an employer w...

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp
Relentless Health ValueOctober 07, 2026
532
37:2034.17 MB

EP532: Why Avoidable ER Visits Aren't the Real Cost Problem: Revisiting Our 2016 Interview With HHS Nominee Chris Klomp

Listen on Your Favorite App Today we are dipping into the archives for an essential replay from 2016, one decade ago, featuring Chris Klomp back when he served as CEO of a company called Collective Medical. With the nomination of Chris Klomp to serve as deputy secretary of the Department of Health a...

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson
Relentless Health ValueSeptember 30, 2026
531
38:0634.88 MB

EP531: Slaying the Three-Headed Monster of Health Plan Networks, With Evan Anderson

Listen on Your Favorite App Today, Evan Anderson and I are talking about carrier networks, how they started, how it's going. Because irrespective of whatever the plan was at the very beginning, any given network, especially talking about the big status quo networks, has evolved into what I'll call a...

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh
Relentless Health ValueSeptember 23, 2026
530
37:4534.56 MB

EP530: A Wildly Underappreciated Point: Overpaying for Infusions Means Overpaying for Stop-Loss Coverage, With Jake Velie and Keith Hartman, RPh

Listen on Your Favorite App Hello, all you Relentless Tribe members. Thanks for hanging with me this week. When a self-insured plan sponsor sees an infusion claim hit their high-cost case report, and a lot of these infusions are really expensive, so many of them hit the high-cost claim report. For a...

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD
Relentless Health ValueSeptember 16, 2026
529
39:2936.14 MB

EP529: How Stark Law, Stipends, and Noncompetes Drive Hospital Consolidation, With Eric Bricker, MD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Hey, thanks for being here with me every week, some of you every single Thursday. Give yourself a little round of applause, maybe silently and in your own head, depending on where you are. But yeah, you matter. You being here matte...

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD
Relentless Health ValueSeptember 09, 2026
528
38:4935.53 MB

EP528: The Current State of Primary Care—Inevitable or Fixable? Will It Be Private Equity to the Rescue? With Yashaswini Singh, PhD

Listen on Your Favorite App Hello, all you Relentless Tribe members. Here's the backstory for this episode. Remember episode 519 with Lisa Rosenbaum, MD, where we played a high-stakes kind of game show called "Is the Current State of Primary Care an Absolute Inevitability, or Is It a Needless, Subop...

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl
Relentless Health ValueAugust 26, 2026
526
20:1119.06 MB

EP526: Generic Compliance Ratios, Pass-Through Contracts, and Other Pharmacy Plumbing, With Mark Cuban and Cora Opsahl

Listen on Your Favorite App Hello, all you Relentless Tribe members. If you have listened to this show for any length of time, you know one of our favorite truths around here, which is where there's mystery, there's margin. But today, we aren't just here to point out the mystery. We're here to look ...

Listen and Follow

Sponsored by Aventria Health Group
©2026 BD Bridges LLC. All Rights Reserved.